Benign Prostatic Hyperplasia Therapeutics Market Brief Analysis on Top Key players Abbott Laboratories, Allergan plc, Astellas Pharma, Boehringer Ingelheim Pharma GmbH, Eli Lilly & Company, GlaxoSmithKline plc, Merck & Co.

The global benign prostatic hyperplasia therapeutics market was valued at $10,688.72 million in 2017, and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025. Benign prostatic hyperplasia (BPH) is a medical condition involving enlargement of the prostate gland and is highly prevalent in males. It is a non-cancerous growth of the prostate gland originating from an uncontrolled expansion of prostate cells. The common symptoms associated with BPH include frequent urination, urine initiation difficulties, weak urinary system, and inability to empty the urinary bladder. Currently, medications are the common way to treat men with mild to moderate BPH. Treatment with drugs, such as alpha blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, antimuscarinics, and others, offers a way of avoiding or postponing surgery. These types of drugs are considered as the most appropriate first-line treatment of the BPH condition.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4708?utm_source=OPR

Benign prostatic hyperplasia (BPH) is a medical condition in which a males prostate gland size increases abnormally. This condition results in problems to start urination, weak urine stream, inability to empty the urinary bladder, and enhanced urine frequency usually at night. BPH therapeutics are drugs categorized into three different classes namely, alpha blocker, 5-alpha reductase inhibitor, and phosphodiesterase-5 inhibitor. These drugs relax the smooth bladder muscles or shrink the abnormal prostate growth to alleviate the BHP symptoms. The relaxation of the muscles of the bladder loosens the prostates grip on the urethra facilitating urine to flow more freely. Whereas, the shrinkage of the size of the prostate reduces the pressure exerted by the prostate on the urethra, resulting in free flow of urine.

Increasing prevalence of benign prostatic hyperplasia, rising global geriatric population, and soaring awareness related to urological disorders and prostate cancer across the world are the factors that drive the global benign prostatic hyperplasia therapeutics market growth. However, higher adoption rate of minimally-invasive surgical therapies instead of BPH therapeutics is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and presence of several pipeline products are expected to provide many opportunities during the forecast period.

The utilization rate of alpha blockers is high, owing to high availability of these products characterized by a higher success rate and lesser side effects. However, the 5-alpha reductase inhibitor segment is expected to grow at a high CAGR during the forecast period.

The mono drug therapy segment is the largest segment in the global benign prostatic hyperplasia therapeutics market, expanding at a moderate CAGR during the forecast period. On the other hand, the combination drug therapy segment is anticipated to record a high CAGR during the forecast period.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/4708?utm_source=OPR

North America was the leading revenue contributor to the global benign prostatic hyperplasia therapeutics market in 2017, and is expected to dominate the market during the forecast period. This is attributed to the early approval of BPH drugs and high adoption of drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness towards safe BPH drugs.

The key players of the global benign prostatic hyperplasia therapeutics market include

• Abbott Laboratories,
• Allergan plc,
• Astellas Pharma, Inc.,
• Boehringer Ingelheim Pharma GmbH & Co. KG,
• Eli Lilly and Company,
• GlaxoSmithKline plc,
• Merck & Co., Inc.,
• Pfizer, Inc.,
• Sanofi, and
• Teva Pharmaceutical Industries Limited.

Table Of Content


Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2017
3.4. Porter’s Five Forces analysis

3.4.1. Bargaining power of buyers
3.4.2. Bargaining power of suppliers
3.4.3. Threat of substitution
3.4.4. Threat of new entrant
3.4.5. Competitive rivalry

3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Rise in in geriatric population
3.5.1.2. Rise in prevalence of benign prostatic hyperplasia
3.5.1.3. Growth in the awareness related to urological disorders and prostate cancer

3.5.2. Restraints

3.5.2.1. High preferences for minimally invasive surgical therapies

3.5.3. Opportunities

3.5.3.1. Large number of products in pipeline
3.5.3.2. Opportunities in emerging economies

3.5.4. Impact analyses

3.6. Clinical trials

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/benign-prostatic-hyperplasia-therapeutics-market.html?utm_source=OPR

About Us:

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.